Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate.
BCR/ABL-positive acute myeloid leukemia (AML) is a rare disease, characterized by a poor prognosis, with resistance to induction chemotherapy and frequent relapses in responsive patients. Here we report a case of BCR/ABL-positive AML-M6 who, after relapse, was treated with Imatinib Mesylate (600 mg/die) and within 4 months achieved a cytogenetic and molecular complete response. After more than 4 years of continuous Imatinib therapy, nested RT-PCR for BCR/ABL is persistently negative. The case reported shows that the response obtained with Imatinib Mesylate in BCR/ABL-positive AML may be long lasting, offering a chance of successful treatment for this poor prognosis group of patients.
Pompetti
Franca
F
Molecular Biology Laboratory, Department of Transfusional Medicine, Ospedale Civile Spirito Santo, Pescara-Italy.
Spadano
Antonio
A
Sau
Antonella
A
Mennucci
Antonio
A
Russo
Rosa
R
Catinella
Virginia
V
Franchi
Paolo Guanciali
PG
Calabrese
Giuseppe
G
Palka
Giandomenico
G
Fioritoni
Giuseppe
G
Iacone
Antonio
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D020732:Cytogenetic Analysis; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D004915:Leukemia, Erythroblastic, Acute / Q000188:drug therapy* / Q000235:genetics; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl